The peptide was discovered in 2015, and human clinical data remain scarce
During a three-week treatment period, both Cagrilintide and salmon calcitonin (sCT), another amylin receptor agonist, produced an acute reduction in food intake in WT mice on day 1 by 53% and 42%, respectively, but not in RAMP1/3 KO mice
However, all observed effects derive from animal models and in vitro research systems
Results are more visible when GHK-Cu is combined with complementary treatments such as microneedling or PRP
In many cases, individuals may transition to a maintenance phase where injections are administered less frequently, such as once every two weeks or once a month
This damage can lead to a condition known as fatty liver disease